*ST生物(000504.SZ)延期回覆深交所重組問詢函
格隆匯11月12日丨ST生物(000504.SZ)公佈,公司於2019年11月5日收到深交所《關於對南華生物醫藥股份有限公司的重組問詢函》(非許可類重組問詢函〔2019〕第9號),要求公司就相關問題做出書面説明,並在11月12日前將有關説明材料報送深交所公司管理部,並及時履行信息披露義務。
收到問詢函後,公司高度重視,積極組織相關部門及中介機構共同對問詢函中涉及的問題進行逐項分析和解答。由於此次回覆內容需進一步核查補充,為確保回覆內容的準確與完善,經向深交所申請,公司將延期回覆問詢函,並儘快完成問詢函回覆工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.